
TL13-112
CAS No. 2229037-19-6
TL13-112( —— )
Catalog No. M13566 CAS No. 2229037-19-6
TL13-112 is a novel Anaplastic Lymphoma Kinase (ALK)-PROTAC developed through conjugation of LDK378 and the cereblon ligand pomalidomide.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 284 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameTL13-112
-
NoteResearch use only, not for human use.
-
Brief DescriptionTL13-112 is a novel Anaplastic Lymphoma Kinase (ALK)-PROTAC developed through conjugation of LDK378 and the cereblon ligand pomalidomide.
-
DescriptionTL13-112 is a novel Anaplastic Lymphoma Kinase (ALK)-PROTAC developed through conjugation of LDK378 and the cereblon ligand pomalidomide; also promotes the degradation of additional kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).
-
In VitroTL13-112 binds to cereblon with an IC50 value of 2.4 uM.TL13-112 (0.01 μM-1 μM; 16 hours)?is selective for degradation of ALK with the DC50s of 10 nM and 40 nM in H3122 cell and Karpas 299, respectively. ALK degradation acts at 4 hours of treatment in H3122 cells and at 8 hours of treatment in Karpas 299 cells. The maximum degradation achieves at 16 hours in both cell lines. .TL13-112 (0.01 μM-1 μM; 16 hours) inhibits PTK2, ALK, FER, RPS6KA1 and Aurora A expression as a dose-dependent manner in H3122, Karpas 299, and Kelly cells. Western Blot Analysis Cell Line:H3122 and Karpas 299 cells Concentration:0.01 μM; 0.05 μM; 0.1 μM; 0.5 μM; 1 μM Incubation Time:16 hours Result:Inhibited ALK and Aurora A expression completely at 1 μM.Western Blot Analysis Cell Line:H3122 and Karpas 299 cells Concentration:0.01 μM; 0.05 μM; 0.1 μM; 0.5 μM; 1 μM Incubation Time:16 hours Result:Decreased PTK2, ALK, FER, RPS6KA1 and Aurora A expression.
-
In Vivo——
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPROTAC
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2229037-19-6
-
Formula Weight1002.582
-
Molecular FormulaC49H60ClN9O10S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (99.74 mM)
-
SMILESCC1=CC(=C(C=C1C2CCN(CC2)CCOCCOCCNC(=O)CNC3=CC=CC4=C3C(=O)N(C4=O)C5CCC(=O)NC5=O)OC(C)C)NC6=NC=C(C(=N6)NC7=CC=CC=C7S(=O)(=O)C(C)C)Cl
-
Chemical NameN-(2-(2-(2-(4-(4-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)-amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)-piperidin-1-yl)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Powell CE, et al. J Med Chem. 2018 May 10;61(9):4249-4255.
molnova catalog



related products
-
Lenalidomide-OH
Lenalidomide-OH is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein.
-
BI-3663
BI-3663 (BI 3663) is a cereblon-based degrader (PROTAC) of Focal adhesion tyrosine kinase (PTK2/FAK) with a median DC50 of 30 nM to >80% across a panel of eleven HCC cell lines.
-
THAL-SNS-032
THAL-SNS-032 is a novel CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).